<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381247</url>
  </required_header>
  <id_info>
    <org_study_id>VV HVAPNOR</org_study_id>
    <nct_id>NCT04381247</nct_id>
  </id_info>
  <brief_title>Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway</brief_title>
  <acronym>HVAPNOR</acronym>
  <official_title>Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      HVAPNOR consists of Three work packages:&#xD;
&#xD;
        1. Prospective observational study of Hospital (HAP) - and ventilator-Associated pneumonia&#xD;
           (VAP) at 5 hospitals in Norway. Establish optimized routines for microbiological&#xD;
           sampling, diagnostics and antibiotic stewardship..&#xD;
&#xD;
        2. Biomarker studies in HAP and VAP.&#xD;
&#xD;
        3. Studies on capacity building in HAP and VAP diagnostics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower respiratory tract infections include hospital-acquired pneumonia (HAP) and ventilator-&#xD;
      associated pneumonia (VAP) with a very high mortality in critically ill patients. Diagnosis&#xD;
      is difficult with an inherent uncertainty and complicated by comorbidity, lack of routines&#xD;
      for high-quality airway sampling and low sensitivity of routine microbiological tests. There&#xD;
      is limited data on the aetiology and burden from HAP and VAP, and to the investigators&#xD;
      knowledge, no previous prospective HAP and VAP studies has been performed in Norway. In the&#xD;
      absence of rapid and accurate microbiological diagnosis, seriously ill HAP and VAP patients&#xD;
      are often provided broad-spectrum antibiotics that have to be active on putative multi-drug&#xD;
      resistant (MDR) bacteria, as failure to initiate prompt adequate therapy is associated with&#xD;
      increased mortality. Overuse of broad-spectrum antibiotics promotes the selection and&#xD;
      dissemination of MDR bacteria.&#xD;
&#xD;
      HVAPNOR brings together a multidisciplinary research team from Norwegian (Haukeland&#xD;
      University Hospital (HUS), University of Bergen (UoB), Vestre Viken Hospital Trust (VVHF),&#xD;
      and international institutions (Denmark, Netherlands and United Kingdom), with a strong&#xD;
      record in respiratory disease research.&#xD;
&#xD;
      The overall aims of the HVAPNOR study are to improve diagnostic methods, antibiotic&#xD;
      stewardship, treatment and management of HAP and VAP. The investigators will in a Norwegian&#xD;
      context, map the incidence and the aetiology of HAP/VAP infections. During a two-year period,&#xD;
      adult HAP and VAP patients admitted at HUS and VVHF, will be identified and voluntarily&#xD;
      included in a prospective descriptive study. The project will strengthen the routines for&#xD;
      adequate airway sampling and assess if provision of ultra-rapid, high-quality accurate&#xD;
      molecular diagnostics will provide a more comprehensive microbiological etiological diagnose&#xD;
      than routine analysis. A direct feedback to the clinician can facilitate pathogen-directed&#xD;
      usage of antibiotics. We will evaluate the potential of molecular diagnostic platforms for&#xD;
      the detection of pathogens and antimicrobial markers in HAP and VAP. Furthermore, the&#xD;
      investigators will identify barriers that inhibit the acceptance of rapid molecular tests;&#xD;
      and contribute to the optimisation of treatment protocols for HAP and VAP.&#xD;
&#xD;
      Finally, the study will also evaluate and identify new and clinically relevant diagnostic and&#xD;
      prognostic biomarkers, including immune biomarkers and transcriptional profiling, in HAP and&#xD;
      VAP.&#xD;
&#xD;
      The HVAPNOR study is in line with the objectives of the funding agencies, addresses clinical&#xD;
      research activities to help to ensure that patients receive high-quality and reliable&#xD;
      diagnostics and optimized treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Time to microbiological diagnose</measure>
    <time_frame>September 2020-August 2022</time_frame>
    <description>Hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiological diagnose</measure>
    <time_frame>September 2020-August 2022</time_frame>
    <description>Microbes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of resistance mutations</measure>
    <time_frame>September 2020-August 2022</time_frame>
    <description>Types and numbers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from empirical to targeted antimicrobial treatment</measure>
    <time_frame>September 2020-August 2022</time_frame>
    <description>Percentage based upon optimized microbiological diagnostics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to targeted antimicrobial treatment</measure>
    <time_frame>September 2020-August 2022</time_frame>
    <description>Hours</description>
  </primary_outcome>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Hospital-acquired Pneumonia</condition>
  <condition>Infectious Disease</condition>
  <condition>Infection, Hospital</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Molecular diagnostics in HAP and VAP</intervention_name>
    <description>Airway samples will be analyzed both by standard and molecular based microbiological analysis.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Airway sampling, Whole blood, serum, plasma, faecal and urinary samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients developing pneumonia during hospital stay for other cause.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        A case definition of NV-HAP and VAP will be applied according to the 2005 American Thoracic&#xD;
        Society and Infectious Disease Society of America´s clinical practice guidelines (unchanged&#xD;
        in the 2016 revision).&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Meets case definition criteria (patient admitted to hospital or endotracheal&#xD;
             intubation ≥ 48 hours, a new lung infiltrate + ≥2 of the following: temperature &gt;38˚C,&#xD;
             leukocytes &lt;3.5 or &gt;11.0, purulent secretions)&#xD;
&#xD;
          -  Eligible for lower airways sampling&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pulmonary embolism, segmental or larger&#xD;
&#xD;
          -  Refractory septic shock (meeting the Sepsis-3 definition of septic shock, and&#xD;
             requiring vasopressors ≥ 0.5 mcg/kg/min noradrenaline or equivalent dose of other&#xD;
             vasopressor(s)&#xD;
&#xD;
          -  Glasgow Coma Scale score 3&#xD;
&#xD;
          -  Patients not eligible for lower airways sampling&#xD;
&#xD;
          -  Palliative situation with life expectancy &lt; 1 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Heggelund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vestre Viken Hospital Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harleen Grewal, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elling Ulvestad, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Heggelund, MD, PhD</last_name>
    <phone>+47 48285882</phone>
    <email>lars.heggelund@vestreviken.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harleen Grewal, MD, PhD</last_name>
    <phone>+47 99450554</phone>
    <email>harleen@grewal@uib.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vestre Viken Health Trust</name>
      <address>
        <city>Drammen</city>
        <state>Viken</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Lars Heggelund, MD; PhD</last_name>
      <phone>+47 482 85 882</phone>
      <email>lars.heggelund@vestreviken.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>hospital-acquired pneumonia</keyword>
  <keyword>ventilator-associated pneumonia</keyword>
  <keyword>molecular diagnostics</keyword>
  <keyword>biomarker</keyword>
  <keyword>antibiotic stewardship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, SAP and ICF will be made avialbe after the study has been initiated. CSR will be made avialbel after publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>September 2020-December 2024.</ipd_time_frame>
    <ipd_access_criteria>PI must be contacted</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

